Tesamorelin is an analogue of the full growth hormone releasing hormone molecule, and the only peptide in this entire group with a drug approval behind it. Sold here as research material, not as a medicine.
Genheal, 10 mg
200,00 złAdd to cart2 in stock (can be backordered)
What is in the vial
Genheal is the only manufacturer offering tesamorelin in this catalogue, in a 10 mg vial of lyophilised powder. A 10 mg vial with 2 ml of bacteriostatic water gives 5 mg per millilitre; the arithmetic and the conversion into insulin syringe units are in the guides on reconstitution and syringe units.
The approved product
The United States Food and Drug Administration approved tesamorelin on 10 November 2010 under the name Egrifta. The indication is narrow: reduction of excess abdominal fat in patients with HIV and lipodystrophy. The prescribing information gives a dose of 2 mg subcutaneously once daily, into the abdomen, rotating the injection site and avoiding scars, bruises and the navel.
Two limits stated on the label itself
The medicine is not indicated for weight reduction: in clinical trials tesamorelin did not change patients’ overall body weight, it changed the distribution of fat tissue. And long-term cardiovascular safety has not been established. Both sentences come from the label, not from us.
The dose above describes the registered medicine. It is not a recommendation, and the research material sold here is not Egrifta.
Why an approval is not a transfer of quality
An approved indication says that a molecule was tested and reviewed for one specific group of patients. It says nothing about a vial bought as research material: not about its content, its purity or its handling before it reached the shop. That is why this page describes the medicine and the vial as two separate things, and why the certificate of analysis matters as much here as on any other page. The wider story of this molecule is in the guide on tesamorelin as the only approved GHRH analogue.
Status
Registered as a medicine in the United States for the indication above. As a GHRH analogue it is prohibited in sport at all times under category S2. The rest of this family, and how the short and long-acting analogues differ, is covered in the growth hormone peptides guide.
Handling and verification
Supplied as lyophilised powder. Storage rules change once it is dissolved: see storage. Check the code under the hologram and the batch certificate as described in check your product. We ship within Poland and abroad; outside Poland the cost is quoted individually, depending on weight and destination country. Details: shipping and payments.
Questions
Is tesamorelin approved as a medicine?
Yes, in the United States, as Egrifta, for reduction of excess abdominal fat in patients with HIV and lipodystrophy. That is the whole indication.
Does it cause weight loss?
Not according to its own label. In the trials it changed the distribution of fat tissue without changing overall body weight.
Is the vial sold here the same as Egrifta?
No. It is research material: no medicine dose, no pharmaceutical quality control, no product information.
Is it allowed in sport?
No. GHRH analogues are prohibited at all times under category S2.